Tonix Pharmaceuticals awarded up to $34M U.S. DoD contract

Tonix Pharmaceuticals has been awarded an Other Transaction Agreement with a potential for up to $34 million over five years by the Defense Threat Reduction Agency, an agency within the U.S. Department of Defense. The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix’s program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug submission and to fund a first-in-human Phase 1 clinical study.